Santa Clara, Calif., Sept. 6, 2016 — Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance metabolic disease and oncology research, will be announcing the release of its new translational platforms for metabolic disease and nonalcoholic fatty liver disease (NASH) during the 52nd Annual Meeting of the European Association for the Study of Diabetes (EASD), September 13-15, in Munich, Germany.
With the acquisition of PreClinOmics earlier this year, CrownBio has further expanded its translational technology platforms for cardiovascular and metabolic disease (CVMD) research, now offering models and services for every stage of the drug discovery process. CrownBio’s scientists will be available at booth B01 for the duration of EASD, and data will be presented at 11 a.m., 2 p.m. and 4 p.m. every day to introduce the company’s growing CVMD portfolio.
“We want to solve the most pressing scientific challenges in cardiovascular and metabolic disease research,” said Jean-Pierre Wery, Ph.D., CEO, Crown Bioscience. “Discussing our latest developments with the leaders in the industry will spark new ideas for the exploration of these complex diseases.”
In addition to introducing its newly developed CVMD translational platform featuring the ZDSD model of polygenic obesity and spontaneous diabetes, CrownBio will present new data on the development of preclinical solutions for NASH research, a therapeutic area with a high unmet need of models for pharmacological evaluation.
For more information on CrownBio’s growing portfolio of models and services for CVMD drug discovery, visit www.crownbio.com.
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development service company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, please visit www.crownbio.com.